Asunto(s)
Antibacterianos/uso terapéutico , Fiebre Tifoidea/tratamiento farmacológico , Antibacterianos/farmacología , Cefalosporinas/farmacología , Cefalosporinas/uso terapéutico , Niño , Farmacorresistencia Bacteriana , Fluoroquinolonas/farmacología , Fluoroquinolonas/uso terapéutico , Humanos , Salmonella typhi/efectos de los fármacosAsunto(s)
Malaria Falciparum/diagnóstico , Malaria Falciparum/tratamiento farmacológico , Animales , Antiinfecciosos/uso terapéutico , Antígenos de Protozoos , Antimaláricos/uso terapéutico , Artemisininas/uso terapéutico , Niño , Humanos , Plasmodium falciparum/inmunología , Quinina/uso terapéutico , Sesquiterpenos/uso terapéuticoRESUMEN
Rabies is a cent per cent fatal disease and there should not be any controversy in giving rabies vaccine to the victims. WHO has fixed schedules for doses for both pre and post-exposure in different category of cases, which also help us to avoid all controversies. But controversies arise in five main areas, which are related to the strategies of rabies prevention. These are: (i) Replacing use of NTV by MTCV. (ii) Intradermal schedule of MTCV, in place of Essen protocol of 5 i.m. doses to reduce the cost. (iii) Acceptability and inclusion of pre-exposure doses of MTCV in the immunization schedule of children as additional vaccine (iv) Schedule for re-exposure in already post-exposure vaccinated cases and schedule for exposure in pre-exposure vaccinated cases. (v) Uses of RIG in WHO category III cases. If these controversial issues are considered scientifically, rabies prophylaxis will see the light of success.